Premium Nahrungsergänzungsmittel | artgerecht

CDAI – Crohn's Disease Activity Index Explained

The CDAI (Crohn's Disease Activity Index) is a clinical scoring tool used to measure disease activity in Crohn's disease. It helps physicians objectively assess the severity of the condition.

Regular tips about health Regular tips about health

Things worth knowing about "CDAI"

The CDAI (Crohn's Disease Activity Index) is a clinical scoring tool used to measure disease activity in Crohn's disease. It helps physicians objectively assess the severity of the condition.

What is the CDAI?

The CDAI (Crohn's Disease Activity Index) is a standardized scoring system used to quantify disease activity in Crohn's disease – a chronic inflammatory bowel condition. It was developed in 1976 by Best and colleagues and remains one of the most widely used tools in both clinical research and gastroenterological practice.

How is the CDAI Calculated?

The CDAI is based on eight clinical variables documented over a period of 7 days. Each variable is multiplied by a specific weighting factor and then summed to produce the final score:

Number of liquid or soft stools per day (factor 2)
Abdominal pain (factor 5, scale 0–3)
General well-being (factor 7, scale 0–4)
Complications (e.g., arthritis, skin manifestations, fistulas) (factor 20)
Use of antidiarrheal medications (factor 30)
Abdominal mass (palpable resistance in the abdomen) (factor 10)
Hematocrit (deviation from normal value) (factor 6)
Body weight (percentage deviation from ideal weight) (factor 1)

Interpretation of the CDAI Score

The total score allows classification of disease activity into distinct severity categories:

Below 150 points: Remission (inactive disease)
150–219 points: Mild disease activity
220–450 points: Moderate disease activity
Above 450 points: Severe disease activity

Clinical Relevance

The CDAI is primarily used in clinical trials to evaluate new therapies for Crohn's disease. A decrease in the CDAI score of at least 100 points is considered a clinically meaningful treatment response. A CDAI value below 150 points corresponds to clinical remission.

In everyday clinical practice, the CDAI is sometimes complemented or replaced by simpler tools such as the Harvey-Bradshaw Index (HBI), as the seven-day documentation process can be burdensome. Nevertheless, the CDAI remains the gold standard for assessing Crohn's disease activity in research settings.

Limitations of the CDAI

Despite its widespread use, the CDAI has several notable limitations:

It does not always correlate with endoscopic or histological disease activity.
Subjective parameters such as abdominal pain and general well-being can reduce objectivity.
In patients who have undergone bowel surgery, the score may be less informative.
The daily documentation required over one week can be demanding for patients.

References

Best WR et al. – Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology, 1976;70(3):439–444.
Peyrin-Biroulet L et al. – Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology, 2015.
European Crohn's and Colitis Organisation (ECCO) – ECCO Guidelines on Crohn's Disease, 2023. Available at: www.ecco-ibd.eu

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.